<?xml version="1.0" encoding="UTF-8"?>
<document id="29857117">
	<sentence id="s1" text="In this study, we investigated the anticancer activity of CP-673451, a potent and selective inhibitor of PDGFRb, on NSCLC cell lines (A549 and H358) and the potential mechanism.">
		<entity id="s1.e1" charOffset="39-45"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<entity id="s1.e2" charOffset="58-60"
			type="GENE" text="CP" ontology_id="1356"/>
		<entity id="s1.e3" charOffset="105-111"
			type="GENE" text="PDGFRb" ontology_id="5159"/>
		<pair id="s1.p1" e1="s1.e1"
		    e2="s1.e2" pgr="false"/>
		<pair id="s1.p2" e1="s1.e1"
		    e2="s1.e3" pgr="true"/>
	</sentence>
	<sentence id="s2" text="Specifically, Nrf2 plays an indispensable role in NSCLC cell sensitivity to platinum-based treatments and we found that combination of CP-673451 and cisplatin produced a synergistic anticancer effect and substantial ROS production in vitro.">
		<entity id="s2.e1" charOffset="135-137"
			type="GENE" text="CP" ontology_id="1356"/>
		<entity id="s2.e2" charOffset="186-192"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<pair id="s2.p1" e1="s2.e1"
		    e2="s2.e2" pgr="false"/>
	</sentence>
</document>
